Drugs vs Mobile: Two Ways To Create $1B in Value

Article Highlights

  • Here are two radically different approaches to creating $1B in value:

    Tweet This

  • Don’t debate the merits of a delightful technology or a reliable drug, but imagine the potential of their intersection.

    Tweet This

  • For the intersection of mobile and health the great challenge will be figuring out how to turn this heat into light.

    Tweet This

This week presents an interesting contrast - two radically different approaches to creating $1B in value.

On Monday, the acquisition of mobile app Instagram by Facebook was announced, shocking some while awing others.  Jon Stewart probably captured the zeitgeist best: "A billion dollars... of money?"  For a smart summary of the deal, see this New York Magazine story (h/t Ruth Coxeter).

Today, URL Pharma was acquired by Takeda for nearly the same amount - $800M.  The story here in brief is that for hundreds of years, colchicine was used for the treatment of gout and other conditions; it was an effective drug but had to be used carefully.  In 2006, the FDA launched the "Unapproved Drug Initiative" offering a period of exclusivity for companies willing to take existing drugs that had never been rigorously validated through an extensive clinical study and FDA approval process. 

URL invested in the formulation development and clinical studies required for colchicine, and ultimately received FDA approval, and associated exclusivity, in 2009.  As a result - patients finally had a "trustworthy" (i.e. FDA-validated) version of colchicine to take, but at a steep price - about 50x what it used to cost.  This has resulted in significant revenue for URL, ultimately leading to today's take-out.

URL and Instagram present two very different approaches to innovation and value; Instagram has created value by coming up with something either imaginative/cool/delightful or utterly trivial, depending on your point of view, while URL has created value by delivering either a reliable important medicine or by focusing on process and working the system, again depending on your point of view.

My own take: rather than debate the relative merits of a delightful technology or a reliable drug, imagine the exceptional potential to be found at the intersection of these worlds.  Right now, there's a lot of energy at the intersection of mobile and health; the great challenge, and opportunity, will be figuring out how to turn this heat into light.

 

Also Visit
AEIdeas Blog The American Magazine
About the Author

 

David
Shaywitz
  • Dr. Shaywitz trained in internal medicine and endocrinology at MGH, and conducted his post-doctoral research in the Melton lab at Harvard. He gained experience in early clinical drug development in the Department of Experimental Medicine at Merck, then joined the Boston Consulting Group’s Healthcare and Corporate Development practices, where he focused on strategy and organizational design. He is currently Director of Strategic and Commercial Planning at Theravance, a publicly-held drug development company in South San Francisco. He recently wrote Tech Tonics: Can Passionate Entreprenuers Heal Healthcare With Technology? 

  • Email: davidshaywitz.aei@gmail.com

What's new on AEI

image Getting it right: US national security policy and al Qaeda since 2011
image Net neutrality rundown: What the NPRM means for you
image The Schuette decision
image Snatching failure from victory in Afghanistan
AEI on Facebook
Events Calendar
  • 21
    MON
  • 22
    TUE
  • 23
    WED
  • 24
    THU
  • 25
    FRI
Wednesday, April 23, 2014 | 12:00 p.m. – 1:30 p.m.
Graduation day: How dads’ involvement impacts higher education success

Join a diverse group of panelists — including sociologists, education experts, and students — for a discussion of how public policy and culture can help families lay a firmer foundation for their children’s educational success, and of how the effects of paternal involvement vary by socioeconomic background.

Thursday, April 24, 2014 | 12:00 p.m. – 1:30 p.m.
Getting it right: A better strategy to defeat al Qaeda

This event will coincide with the release of a new report by AEI’s Mary Habeck, which analyzes why current national security policy is failing to stop the advancement of al Qaeda and its affiliates and what the US can do to develop a successful strategy to defeat this enemy.

Event Registration is Closed
Friday, April 25, 2014 | 9:15 a.m. – 1:15 p.m.
Obamacare’s rocky start and uncertain future

During this event, experts with many different views on the ACA will offer their predictions for the future.   

No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.